As of 2026-03-19, the Relative Valuation of Intellia Therapeutics Inc (NTLA) is (76.42) USD. This relative valuation is based on P/E multiples. With the latest stock price at 13.21 USD, the upside of Intellia Therapeutics Inc based on Relative Valuation is -678.5%.
The range of the Relative Valuation is (72.04) - (81.33) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.0x - 23.9x | 22.2x |
| Forward P/E multiples | 20.6x - 23.3x | 21.6x |
| Fair Price | (72.04) - (81.33) | (76.42) |
| Upside | -645.3% - -715.7% | -678.5% |
| Date | P/E |
| 2026-03-19 | -3.74 |
| 2026-03-18 | -3.78 |
| 2026-03-17 | -3.86 |
| 2026-03-16 | -3.83 |
| 2026-03-13 | -3.65 |
| 2026-03-12 | -3.68 |
| 2026-03-11 | -3.72 |
| 2026-03-10 | -3.86 |
| 2026-03-09 | -3.98 |
| 2026-03-06 | -3.85 |
| 2026-03-05 | -3.76 |
| 2026-03-04 | -3.96 |
| 2026-03-03 | -3.89 |
| 2026-03-02 | -4.42 |
| 2026-02-27 | -3.94 |
| 2026-02-26 | -4.09 |
| 2026-02-25 | -3.84 |
| 2026-02-24 | -3.89 |
| 2026-02-23 | -3.77 |
| 2026-02-20 | -3.62 |
| 2026-02-19 | -3.73 |
| 2026-02-18 | -3.57 |
| 2026-02-17 | -3.50 |
| 2026-02-13 | -3.40 |
| 2026-02-12 | -3.33 |
| 2026-02-11 | -3.43 |
| 2026-02-10 | -3.41 |
| 2026-02-09 | -3.58 |
| 2026-02-06 | -3.52 |
| 2026-02-05 | -3.17 |
| 2026-02-04 | -3.54 |
| 2026-02-03 | -3.74 |
| 2026-02-02 | -3.74 |
| 2026-01-30 | -3.76 |
| 2026-01-29 | -3.98 |
| 2026-01-28 | -3.96 |
| 2026-01-27 | -4.24 |
| 2026-01-26 | -3.99 |
| 2026-01-23 | -4.19 |
| 2026-01-22 | -4.55 |
| 2026-01-21 | -4.02 |
| 2026-01-20 | -3.67 |
| 2026-01-16 | -3.58 |
| 2026-01-15 | -3.40 |
| 2026-01-14 | -3.44 |
| 2026-01-13 | -3.36 |
| 2026-01-12 | -3.27 |
| 2026-01-09 | -2.97 |
| 2026-01-08 | -3.01 |
| 2026-01-07 | -2.90 |